Abstract:Background. Disorders in the production of neuroendocrine peptides in the digestive tract can cause changes in, intestinal motility and the formation of visceral hypersensitivity, characteristic of patients with irritable bowel syndrome (IBS). From this standpoint, of particular interest is the study of the role of a number of major endocrine cells (EC) of the colon, secreting motilin, vasoactive intestinal polypeptide, and somatostatin, in IBS. Aims to evaluate the density of ECs with different hormonal activities that secrete motilin, vasoactive intestinal polypeptide and somatostatin in the mucosa of the sigmoid colon in patients with IBS that occurs with constipation and diarrhea. Materials and methods. 85 patients with IBS were examined. The first group included 44 patients with diarrhea (IBSd), the second group included 41 patients with constipation (IBSc). The comparison group consisted of 36 practically healthy people. The diagnosis of IBS was based on the Rome IV criteria. Patients and healthy people were examined according to a single program, including clinical, instrumental (colonoscopy, ultrasound examination of the abdominal organs), laboratory (clinical blood test, feces for calprotectin and antibodies to gliadin in the presence of diarrhea), morphological and immunohistochemical methods. Results. The clinical picture of IBS corresponded to the classical manifestations of this pathology. Among patients with IBSc, there was a more frequent feeling of incomplete emptying of the intestine after defecation, compared with patients with IBSd (p 0.05). Among patients with IBSd, there was a statistically significant increase in the number of ECs producing motilin and vasoactive intestinal polypeptide, as well as a lower density of ECs secreting somatostatin, compared with the control group (p 0.05). In the IBSc group, there was a decrease in the number of ECs producing motilin, vasoactive intestinal polypeptide and an increase in the number of ECs producing somatostatin, compared with the control group (p 0.05). Conclusions. An increase in the number of cells producing motilin, vasoactive intestinal polypeptide and a decrease in the number of cells observed for the production of somatostatin in the mucosa of the sigmoid colon is characteristic of the manifestation of IBSd. At the same time, an increase in ECs secreting motilin, vasoactive intestinal polypeptide and an increase in cellular elements producing somatostatin reveals manifestations of IBSс.

Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome

Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral Cytokines

Lactose Intolerance In Irritable Bowel Syndrome Patients With Diarrhoea: The Roles Of Anxiety, Activation Of The Innate Mucosal Immune System And Visceral Sensitivity

Correlation of gut hormones with irritable bowel syndrome

Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome

Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome

Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea

Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome

The Role of Endocrine Cells of the Colon, Secreting Vasoactive Intestinal Polypeptide, Somatostatin and Motilin, in Irritable Bowel Syndrome, Occurring with Diarrhea and Constipation

An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome

[Irritable bowel syndrome with extraintestinal manifestations from a position of neuroendocrine pathology]

Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?

Altered vasoactive intestinal peptides expression in irritable bowel syndrome patients and rats with trinitrobenzene sulfonic acid-induced colitis

Enhanced Cholinergic-Mediated Increase in the Pro-Inflammatory Cytokine IL-6 in Irritable Bowel Syndrome: Role of Muscarinic Receptors

Stomach antral endocrine cells in patients with irritable bowel syndrome

Pilot Study of Small Bowel Mucosal Gene Expression in Patients with Irritable Bowel Syndrome with Diarrhea.

Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients

Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome

Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome

Transcriptomic and Metabolomic Correlates of Increased Colonic Permeability in Postinfection Irritable Bowel Syndrome

[Role of gut hormones in irritable bowel syndrome]